Dermatology · Owings Mills, MD
NPI
1578637674
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
10220 South Dolfield Road, Suite #110
Owings Mills, MD, 21117
Phone (410) 356-0000
Medicare paid, 2024
$199K
3,668 services
Medicare patients, 2024
492
Average age 74
Drug cost, 2024
$546K
1,631 prescriptions
Company payments, 2025
$3,107
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Steven B Snyder was code 99213 (office e&m - established), 890 times for 383 patients. In total Steven B Snyder billed 3,668 services in 39 codes, and Medicare paid $199K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 890 | 383 | $68.92 | $61K |
| 17003 Destruction Skin Lesion | Office | 814 | 148 | $5.50 | $4,477 |
| 17110 Destruction Skin Lesion | Office | 352 | 230 | $90.16 | $32K |
| 17000 Destruction Skin Lesion | Office | 302 | 190 | $33.03 | $9,975 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 285 | 15 | $0.76 | $216 |
| 17004 Destruction Skin Lesion | Office | 181 | 92 | $130.10 | $24K |
| 17111 Destruction Skin Lesion | Office | 178 | 118 | $107.90 | $19K |
| 99203 Office E&M - New | Office | 167 | 167 | $80.69 | $13K |
| 11102 Skin Biopsy | Office | 139 | 118 | $53.00 | $7,367 |
| 11200 Removal or Shaving of Skin Growth | Office | 55 | 48 | $40.16 | $2,209 |
| 11103 Skin Biopsy | Office | 49 | 30 | $42.12 | $2,064 |
| 99214 Office E&M - Established | Office | 49 | 43 | $101.84 | $4,990 |
| 10040 Removal or Shaving of Skin Growth | Office | 36 | 33 | $83.50 | $3,006 |
| 11104 Skin Biopsy | Office | 18 | 18 | $93.49 | $1,683 |
By year: 2022 $171K for 2,846 services; 2023 $206K for 3,837 services; 2024 $199K for 3,668 services.
Medicare prescription drug claims, 2024
In 2024, the drug Steven B Snyder prescribed most often to Medicare patients was Betamethasone Dipropionate, with 215 prescriptions and refills. In total Steven B Snyder wrote 1,631 Medicare prescriptions that cost $546K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Betamethasone Dipropionate Generic | 215 | 228 | 105 | $8,856 |
| Ketoconazole Generic | 206 | 222 | 105 | $4,593 |
| Triamcinolone Acetonide Generic | 118 | 135 | 60 | $792 |
| Mupirocin Generic | 105 | 108 | 67 | $1,783 |
| Levocetirizine Dihydrochloride Generic | 104 | 124 | 51 | $1,703 |
| Clobetasol Propionate Generic | 98 | 102 | 52 | $6,168 |
| Mometasone Furoate Generic | 57 | 57 | 38 | $1,594 |
| Jublia Efinaconazole | 53 | 58 | 16 | $68K |
| Doxycycline Hyclate Generic | 50 | 53 | 18 | $604 |
| Clindamycin Phosphate Generic | 43 | 46 | 33 | $1,820 |
| Ammonium Lactate Generic | 42 | 42 | 11 | $1,082 |
| Desonide Generic | 41 | 41 | 23 | $2,069 |
| Cefuroxime Cefuroxime Axetil | 40 | 40 | 19 | $691 |
| Hydrocortisone Generic | 34 | 42 | 19 | $238 |
| Metronidazole Generic | 28 | 30 | 18 | $2,892 |
Brand drugs: 222 claims; generic drugs: 1,409 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Steven B Snyder $3,107 ($3,107 in general payments such as food, travel and fees) from 16 companies. The largest payer was Galderma Laboratories, L.P. with $647.
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. GALD.SW | 26 | $647 |
| LEO Pharma Inc. | 27 | $445 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 17 | $417 |
| UCB, Inc. UCB.BR | 14 | $343 |
| Journey Medical Corporation DERM | 5 | $292 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $184 |
| Arcutis Biotherapeutics, Inc. ARQT | 17 | $165 |
| Genzyme Corporation SNY | 5 | $140 |
| Lilly USA, LLC LLY | 8 | $135 |
| Janssen Biotech, Inc. JNJ | 4 | $100 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.